Reports Q2 revenue $2.1M, consensus $760,000. Verve ended the second quarter of 2023 with $462.5M in cash, cash equivalents, and marketable securities. Verve expects its existing cash, cash equivalents, and marketable securities, including the additional $60M upfront payment and equity investment from Lilly in August 2023, to be sufficient to fund its operations into 2026.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on VERV:
- Verve Therapeutics Highlights Recent Company Progress and Reports Second Quarter 2023 Financial Results
- Verve Therapeutics to Present at the Canaccord 43rd Annual Growth Conference
- Cathie Wood’s ARK Investment bought 96.3K shares of Verve Therapeutics today
- Cathie Wood’s ARK Investment bought 69K shares of Verve Therapeutics today
- Cathie Wood’s ARK Investment bought 113.5K shares of Verve Therapeutics today